AMAG Pharmaceuticals Inc.’s strategy to keep its preterm birth treatment Makena on the US market seems three-fold: raise process concerns with the FDA, rally the product’s allies, and request extensions.
Makena (hydroxyprogesterone caproate injection, also known as HCP or 17P) is slated for removal after the FDA concluded that it...






